Back to top
more

Vical Incorporated (VICL)

(Delayed Data from NSDQ)

$1.16 USD

1.16
102,317

-0.01 (-0.85%)

Updated May 3, 2019 03:57 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Fresh Tracks Therapeutics, Inc. [VICL]

Reports for Purchase

Showing records 1 - 20 ( 117 total )

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

08/15/2019

Daily Note

Pages: 6

The company is dropping coverage of the following stocks

Provider: IFS Securities, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

07/15/2019

Company Report

Pages: 7

Reports 2Q19; Shareholder Vote and Merger Closure Ahead

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

06/03/2019

Company Report

Pages: 8

Vical Enters Into Merger Agreement with Brickell Biotech

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

05/03/2019

Company Report

Pages: 7

Reports 1Q19; Still Looking for a Buyer

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

02/25/2019

Company Report

Pages: 4

Outlook Uncertain Following VL-2397 Program Discontinuation; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

02/21/2019

Company Report

Pages: 6

Vical Scales Back Operations While Looking for a Buyer

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

02/15/2019

Company Report

Pages: 7

Update on Vical: Enrollment in VL-2397 Pivotal Trial Appears On-Track

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

10/30/2018

Company Report

Pages: 4

3Q18 Financial Results Reported; Substantial Spending Drop; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/29/2018

Company Report

Pages: 7

Reports Better Than Expected Financial Results for 3Q2018

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

10/23/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for VICL

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

09/07/2018

Company Report

Pages: 4

We are dropping coverage of VICL shares to reallocate our research resources.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

09/05/2018

Company Report

Pages: 7

Highlights of Vical Presentation at Investor Conference

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

08/08/2018

Company Report

Pages: 4

Financial Results Reported; Awaiting Results of Strategic Options Review; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

08/07/2018

Company Report

Pages: 6

Financial Results of Second Quarter In the Books

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

06/19/2018

Company Report

Pages: 4

VCL-HB-01 Failure Leaves VL-2397 a Standalone Asset; Reiterate Buy and Lowering Target to $3.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

06/12/2018

Company Report

Pages: 12

HSV-2 Vaccine Phase II does not meet endpoints; Re-evaluating VICL based on VL-2397

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/07/2018

Company Report

Pages: 4

1Q 2018 Results Reported; HCL-HB-01 Phase 2 Data Next Month; Cash Runway Solid; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/03/2018

Company Report

Pages: 6

Reports 1Q 2017 Financial Results As Expected

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

03/16/2018

Company Report

Pages: 6

Reports 4Q and FY2017 Financial Results As Expected

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Company: Fresh Tracks Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/16/2018

Company Report

Pages: 4

4Q and FY2017 Financials Reported; Near-Term Catalysts Ahead; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party
// eof